| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 09/16/1999 | WO1999045963A1 Analgesic combination comprising nmda receptor antagonists and narcotic analgesics |
| 09/16/1999 | WO1999045960A1 Enhancement of intracellular delivery and tissue targeting of drugs and genes |
| 09/16/1999 | WO1999045923A1 Methods of inhibiting bone resorption |
| 09/16/1999 | WO1999045920A2 The use of a protein tyrosine inhibitor such as genistein in the treatment of diabetic retinopathy or ocular inflammation |
| 09/16/1999 | WO1999045917A1 Remedies for aids |
| 09/16/1999 | WO1999045915A1 Use of alpha-rar antagonists for inhibition of mucin secretion |
| 09/16/1999 | WO1999045913A1 Combination therapy and composition for acute coronary ischemic syndrome and related conditions |
| 09/16/1999 | WO1999045910A2 Methods and compositions for treating and preventing mucositis |
| 09/16/1999 | WO1999045908A2 Anti-viral uses of leflunomide products |
| 09/16/1999 | WO1999045907A2 Metal chelators for use in the treatment of alzheimer's disease |
| 09/16/1999 | WO1999045905A2 Prophylaxis and treatment of migraine headaches with thromboxane synthetase inhibitors and/or receptor antagonists |
| 09/16/1999 | WO1999045869A1 Use of corneal hardening agents in enzyme orthokeratology |
| 09/16/1999 | WO1999045775A1 Compositions and methods for modulating vascularization |
| 09/16/1999 | WO1999036091A3 Method for inhibiting cd95-independent apoptosis in aids |
| 09/16/1999 | WO1999035243A3 Extension of cellular lifespan, methods and reagents |
| 09/16/1999 | WO1999033355A3 Fat blend |
| 09/16/1999 | WO1999029329A9 Immunotherapy using ie water |
| 09/16/1999 | WO1999029321A9 Inhibition of membrane-associated viral replication |
| 09/16/1999 | DE19910855A1 Composition comprising structured water with pharmaceutical or cosmetic use |
| 09/16/1999 | CA2323448A1 Methods of inhibiting bone resorption |
| 09/16/1999 | CA2323236A1 Human receptor proteins; related reagents and methods |
| 09/16/1999 | CA2323210A1 Enhancement of intracellular delivery and tissue targeting of drugs and genes |
| 09/16/1999 | CA2323199A1 Use of corneal hardening agents in enzyme orthokeratology |
| 09/16/1999 | CA2323089A1 Inhibitors of type 5 and type 3 17.beta.-hydroxysteroid dehydrogenase and methods for their use |
| 09/16/1999 | CA2323070A1 Chitinase chitin-binding fragments |
| 09/16/1999 | CA2323016A1 Multicomponent complex for use with a substrate |
| 09/16/1999 | CA2323015A1 Remedies for aids |
| 09/16/1999 | CA2322824A1 Combination therapy and composition for acute coronary ischemic syndrome and related conditions |
| 09/16/1999 | CA2322503A1 Disposable absorbent article having a skin care composition containing an enzyme inhibitor |
| 09/16/1999 | CA2321935A1 Use of alpha-rar antagonists for inhibition of mucin secretion |
| 09/15/1999 | EP0941364A1 Process aimed at evidencing the state of a malignant cell and process for treatment |
| 09/15/1999 | EP0941345A2 Chimeric, humanized and single chain antibodies to alpha-2-antiplasmin |
| 09/15/1999 | EP0941342A1 Human squalene epoxidase |
| 09/15/1999 | EP0941341A1 Nucleotide sequence coding for a flavin-containing monooxygenase, corresponding protein and their applications in the fields of diagnosis and therapy |
| 09/15/1999 | EP0941328A1 Human breast tumor-specific proteins |
| 09/15/1999 | EP0941327A1 Human g-protein receptor hcegh45, a pacap-like (g-protein pituitary adenylate cyclase activating polypeptide-like) receptor |
| 09/15/1999 | EP0941321A1 Circularly permuted polypeptides as novel stem cell factor receptor agonists |
| 09/15/1999 | EP0941316A1 Human p2x purinoreceptor |
| 09/15/1999 | EP0941313A1 Prostate-specific kallikrein |
| 09/15/1999 | EP0941249A1 Novel histamine h2 receptor |
| 09/15/1999 | EP0941248A1 Platelet secretory transport protein |
| 09/15/1999 | EP0941243A1 Polypeptides comprising gax protein domains, involved in repressing transcription and/or interacting with other proteins, corresponding nucleic acids and their use |
| 09/15/1999 | EP0941239A1 Vertebrate homologues of unc-53 protein of c. elegans |
| 09/15/1999 | EP0941116A2 Therapeutic use of an agent that stimulates no or prostacyclin production and delivery device |
| 09/15/1999 | EP0941115A1 Use of growth hormone or a growth hormone secretagogue for promoting bone formation |
| 09/15/1999 | EP0941111A1 Hepatocyte growth factor antagonists |
| 09/15/1999 | EP0941108A1 Wound healing and treatment of fibrosis |
| 09/15/1999 | EP0941095A1 Improved pharmaceutical compositions |
| 09/15/1999 | EP0941093A1 Use of nk-1 receptor antagonists for treating major depressive disorders with anxiety |
| 09/15/1999 | EP0941092A1 Use of nk-1 receptor antagonists for treating major depressive disorders |
| 09/15/1999 | EP0941089A2 Compositions and methods for treating or preventing inflammatory diseases |
| 09/15/1999 | EP0941086A1 Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses |
| 09/15/1999 | EP0941082A2 New use for 1,3-propanediol derivatives |
| 09/15/1999 | EP0804239B1 Anti-stress, anti-impairment and anti-aging drug and process for manufacturing thereof |
| 09/15/1999 | CN1228703A Chelating agents and their metal chelates for treating free radicals induced conditions |
| 09/15/1999 | CN1228702A Transdermal therapeutical approach involving combination of active substances containing oestriol |
| 09/15/1999 | CN1228698A Antithrombotic and antiatherogenic pharmaceutical composition including thienopyridine derivative and HMG-CoA-reductase inhibitor |
| 09/15/1999 | CN1228697A Method for in vivo reduction of iron levels and compositions useful therefor |
| 09/15/1999 | CN1228696A Use of PKC inhibitors for manufacture of medicament for treatment of AIDS |
| 09/15/1999 | CN1228694A Method of reducing cardiotoxicity of antitumor agent using manganese compound |
| 09/14/1999 | US5952483 Human IκB-β |
| 09/14/1999 | US5952389 Methods of treating tardive dyskinesia and other movement disorders |
| 09/14/1999 | US5952384 Contacting the mammalian cell with an inflammatory mediator selected from the group consists of pyruvate and pyruvate precursor capable of reducing undesired inflammatory response and is antioxidant |
| 09/14/1999 | US5952380 Method for treating diarrhea |
| 09/14/1999 | US5952373 Applying to the skin an effective amount of one or more flavonoids |
| 09/14/1999 | US5952371 Triterpene derivatives with immunosuppressant activity |
| 09/14/1999 | US5952361 Compositions |
| 09/14/1999 | US5952356 Treating diabetes in a mammal with an active material and a glucosidase inhibitor |
| 09/14/1999 | US5952341 Integrin antagonists |
| 09/14/1999 | US5952330 Use of NK-1 receptor antagonists for treating mania |
| 09/14/1999 | US5952329 Contacting cells of tumor with a first chromophore and a second chromophore; exposing said contacted tumor cells to light of a first and second predetermined wavelength and power density and energy level |
| 09/14/1999 | US5952322 Method of reducing tissue damage associated with non-cardiac ischemia using glycogen phosphorylase inhibitors |
| 09/14/1999 | US5952315 Treating physiological disorders, disorders of the central nervous system such as anxiety, depression and psychosis with an antidepressant |
| 09/14/1999 | US5952311 Photosensitizing chemical means for killing tumor cells, wherein tumoricidal activity is activated by absorbing light or energy within a specific wavelength range, and energy donating chemical means for activating photosensitizer |
| 09/14/1999 | US5952305 Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims |
| 09/14/1999 | US5952302 Human therapeutic uses of BPI protein products |
| 09/14/1999 | US5952214 Human growth-related CDC10 homolog |
| 09/14/1999 | US5952181 Hybridizing polynucleotide sequence to complementary polynucleotide forming a complex, detecting complex formation; anticarcinogenic agent, treatment of psychological disorders, alzheimer's disease |
| 09/14/1999 | US5952175 DNA encoding a human progesterone receptor complex p23-like protein |
| 09/14/1999 | US5951984 Administering immunogen selected from group of protein and peptide to mammel, wherein mammel does not ingest a fat-soluble component substance within 4 hours before and within 2 hours after ingestion of the immunogen |
| 09/14/1999 | US5951976 Vaccinating a mammal by administering a composition comprising an opsonin-enhanced cell comprising said selected antigen with the provision the opsonin does not bind to a receptor for a fragment of c33 |
| 09/14/1999 | CA2174598C Use of an inhibitor of an hmg-coenzyme-a reductase to prevent aging of the skin or to stimulate the process of epidermal renewal |
| 09/10/1999 | WO1999045135A1 Novel fdrg protein and nucleic acid molecules and uses therefor |
| 09/10/1999 | WO1999045127A2 Enhanced prodrug activation |
| 09/10/1999 | WO1999045126A2 Enhanced prodrug activation |
| 09/10/1999 | WO1999044645A1 Compositions and methods of treating tumors |
| 09/10/1999 | WO1999044643A1 Implantable particles for tissue bulking and the treatment of gastroesophageal reflux disease, urinary incontinence, and skin wrinkles |
| 09/10/1999 | WO1999044642A1 Pharmaceutical compositions and their use |
| 09/10/1999 | WO1999044641A1 Transmucous sorbefacients |
| 09/10/1999 | WO1999044640A1 Combination of a selective nmda nr2b antagonist and a cox-2 inhibitor |
| 09/10/1999 | WO1999044638A1 Photothermal structure for biomedical applications, and method therefor |
| 09/10/1999 | WO1999044637A1 Method and apparatus for enhancing flux rates of a fluid in a microporated biological tissue |
| 09/10/1999 | WO1999044628A1 Conjugates useful in the treatment of prostate cancer |
| 09/10/1999 | WO1999044623A1 Compositions comprising valerian extracts, isovaleric acid or derivatives thereof with a nsaid |
| 09/10/1999 | WO1999044620A1 Asthma associated factors as targets for treating atopic allergies including asthma and related disorders |
| 09/10/1999 | WO1999044615A1 Use of d1/d5 antagonists for treating obsessive compulsive disorders, somatoform disorders, dissociative, eating disorders, impulse control disorders and autism |
| 09/10/1999 | WO1999044610A1 Combination of a selective nmda nr2b antagonist and an opioid analgesic |
| 09/10/1999 | WO1999044607A1 Use of pkc inhibitors for the manufacture of a medicament for the treatment of autoimmune diseases |
| 09/10/1999 | WO1999044606A1 Use of pkc-inhibitors for the manufacture of a medicament for the treatment of asthma |
| 09/10/1999 | WO1999044605A1 Use of pkc inhibitors for the manufacture of a medicament for the treatment of cytomegalovirus infection |